A limited sampling method for estimation of the carboplatin area under the curve
- 1 January 1993
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 31 (4) , 324-327
- https://doi.org/10.1007/bf00685679
Abstract
Summary A limited sampling method for estimation of the carboplatin area under the curve (AUC) from one or two plasma concentration determination is presented. The model was conceived and developed using 43 pharmacokinetic studies in 15 patients with ovarian cancer (model data set) who received carboplatin in combination with cyclophosphamide. Linear regression analyses comparing the AUC and the drug concentration at a single time point (0.25–10 h after the end of the infusion) as calculated from the fitted exponential equations gave correlation coefficients as high as 0.97, with maximal correlations falling within the interval of 2–3.25 h. The model was validated prospectively in 9 patients with ovarian cancer (validation data set) who received the same treatment as did the model data set (21 pharmacokinetic studies), testing the equation AUC=0.52×C2.75h+0.92. Observed and estimated AUCs were correlated in the validation data set (r=0.91). The mean predictive error (MPE%±SE) was −4.4%±3.1% and the root mean squared error (RMSE%) was 13.9%. Multiple regression analysis revealed that adding a second sample drawn at 0.25 h (AUC=0.053×C0.25h+0.401×C2.75h+0.628) improved the MPE% to −2.2%±2.1% and the RMSE% to 9.4% (r=0.96). We conclude that the carboplatin AUC can be estimated from a single plasma sample at 2.75 h or, more precisely, from two plasma samples at 0.25 and 2.75 h. The methods described may prove to be a handy tool for the calculation of approximate AUCs in trials of a size that would discourage detailed pharmacokinetic studies.Keywords
This publication has 22 references indexed in Scilit:
- Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patientsCancer Chemotherapy and Pharmacology, 1991
- Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancerCancer Chemotherapy and Pharmacology, 1991
- When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?Cancer Chemotherapy and Pharmacology, 1988
- LIMITED SAMPLING MODELS FOR AMONAFIDE (NSC-308847) PHARMACOKINETICS1988
- Liquid Chromatographic Procedure for the Quantitative Analysis of Carboplatin in Beagle Dog Plasma UltrafiltrateJournal of Pharmaceutical Sciences, 1988
- Limited sampling model for vinblastine pharmacokinetics.1987
- Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IICancer Chemotherapy and Pharmacology, 1982
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977
- A Simple Method for the Determination of Glomerular Filtration RateScandinavian Journal of Clinical and Laboratory Investigation, 1972